# Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients

> **NCT03427307** · — · COMPLETED · sponsor: **Tungs' Taichung Metroharbour Hospital** · enrollment: 360 (actual)

## Conditions studied

- Systemic Inflammatory Response Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03427307
- **Lead sponsor:** Tungs' Taichung Metroharbour Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-03
- **Primary completion:** 2018-12-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03427307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03427307, "Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03427307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*